Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
Recruiting · NCT05563467 · Registry updated 2025-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. | Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm | Recruiting | Phase 2 | 2025-04-02 | NCT05563467 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Biostat Sp. z o.o. | 1 |
| Maria Sklodowska-Curie National Research Institute of Oncology | 28 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Maria Sklodowska-Curie National Research Institute of Oncology | Gliwice | Poland | 1 |
| Medical University of Warsaw | Warsaw | Poland | 12 |
| Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki W Krakowie | Cracow | Poland | 1 |
| Uniwersytecki Szpital Kliniczny w Poznaniu | Poznan | Poland | 8 |